Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


New Amedeo service:

Amedeo COVID-19 (formerly 2019-nCoV)

Weekly publication summary


  Schizophrenia

  Free Subscription


Articles published in Am J Psychiatry

Retrieve available abstracts of 100 articles:
HTML format
Text format



Single Articles


    February 2020
  1. JONAS KG, Fochtmann LJ, Perlman G, Tian Y, et al
    Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia.
    Am J Psychiatry. 2020 Feb 12:appiajp201919030324.
    PubMed     Text format     Abstract available


  2. HJORTHOJ C, Starzer MSK, Benros ME, Nordentoft M, et al
    Infections as a Risk Factor for and Prognostic Factor After Substance-Induced Psychoses.
    Am J Psychiatry. 2020 Feb 12:appiajp201919101047.
    PubMed     Text format     Abstract available


  3. KALIN NH
    Treating Substance Use Disorders, Binge Eating, and Depression, and Identifying Factors Underlying Psychosis Risk.
    Am J Psychiatry. 2020;177:101-103.
    PubMed     Text format    


    January 2020
  4. KENDLER KS
    Maternal Bacterial Infection During Pregnancy: A Potential Causal Risk Factor for Psychosis in Offspring.
    Am J Psychiatry. 2020;177:14-16.
    PubMed     Text format    


    December 2019
  5. LEUCHT S, Crippa A, Siafis S, Patel MX, et al
    Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
    Am J Psychiatry. 2019 Dec 16:appiajp201919010034.
    PubMed     Text format     Abstract available


  6. DICKINSON D, Zaidman SR, Giangrande EJ, Eisenberg DP, et al
    Distinct Polygenic Score Profiles in Schizophrenia Subgroups With Different Trajectories of Cognitive Development.
    Am J Psychiatry. 2019 Dec 16:appiajp201919050527.
    PubMed     Text format     Abstract available


  7. RAGLAND JD
    Relating Basal and Phasic Hippocampal Activity in People With Psychosis: A Translational Bridge to Understanding Memory Deficits?
    Am J Psychiatry. 2019;176:979-981.
    PubMed     Text format    


    November 2019
  8. PERKINS DO, Olde Loohuis L, Barbee J, Ford J, et al
    Polygenic Risk Score Contribution to Psychosis Prediction in a Target Population of Persons at Clinical High Risk.
    Am J Psychiatry. 2019 Nov 12:appiajp201918060721.
    PubMed     Text format     Abstract available


    October 2019
  9. MCHUGO M, Talati P, Armstrong K, Vandekar SN, et al
    Hyperactivity and Reduced Activation of Anterior Hippocampus in Early Psychosis.
    Am J Psychiatry. 2019 Oct 18:appiajp201919020151.
    PubMed     Text format     Abstract available


  10. KARLSGODT KH
    Using Advanced Diffusion Metrics to Probe White Matter Microstructure in Individuals at Clinical High Risk for Psychosis.
    Am J Psychiatry. 2019;176:777-779.
    PubMed     Text format    


  11. KALIN NH
    Gaining Ground on Schizophrenia: Conceptualizing How to Use Neuroimaging and Genomics in Its Diagnosis and Treatment.
    Am J Psychiatry. 2019;176:771-773.
    PubMed     Text format    


  12. GUR RE, Gur RC
    Functional MRI Predicting Intervention Outcome in Early Psychosis.
    Am J Psychiatry. 2019;176:780-782.
    PubMed     Text format    


  13. BINDER EB
    Polygenic Risk Scores in Schizophrenia: Ready for the Real World?
    Am J Psychiatry. 2019;176:783-784.
    PubMed     Text format    


  14. LIEBERMAN JA, Small SA, Girgis RR
    Early Detection and Preventive Intervention in Schizophrenia: From Fantasy to Reality.
    Am J Psychiatry. 2019;176:794-810.
    PubMed     Text format     Abstract available


  15. KAHN RS
    On the Specificity of Continuous Cognitive Decline in Schizophrenia.
    Am J Psychiatry. 2019;176:774-776.
    PubMed     Text format    


    September 2019
  16. DUGRE JR, Bitar N, Dumais A, Potvin S, et al
    Limbic Hyperactivity in Response to Emotionally Neutral Stimuli in Schizophrenia: A Neuroimaging Meta-Analysis of the Hypervigilant Mind.
    Am J Psychiatry. 2019 Sep 6:appiajp201919030247.
    PubMed     Text format     Abstract available


  17. ALLSWEDE DM, Addington J, Bearden CE, Cadenhead KS, et al
    Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains.
    Am J Psychiatry. 2019 Sep 6:appiajp201918111290.
    PubMed     Text format     Abstract available


  18. APPELBAUM PS
    In Search of a New Paradigm for Research on Violence and Schizophrenia.
    Am J Psychiatry. 2019;176:677-679.
    PubMed     Text format    


  19. TANDON R, Shariff SM
    Substance-Induced Psychotic Disorders and Schizophrenia: Pathophysiological Insights and Clinical Implications.
    Am J Psychiatry. 2019;176:683-684.
    PubMed     Text format    


    August 2019
  20. ZHEUTLIN AB, Dennis J, Karlsson Linner R, Moscati A, et al
    Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia in 106,160 Patients Across Four Health Care Systems.
    Am J Psychiatry. 2019 Aug 16:appiajp201918091085.
    PubMed     Text format     Abstract available


    July 2019
  21. KOCHUNOV P, Huang J, Chen S, Li Y, et al
    White Matter in Schizophrenia Treatment Resistance.
    Am J Psychiatry. 2019 Jul 29:appiajp201918101212.
    PubMed     Text format     Abstract available


  22. ESCOTT-PRICE V, Pardinas AF, Santiago E, Walters J, et al
    The Relationship Between Common Variant Schizophrenia Liability and Number of Offspring in the UK Biobank: Response to Lawn et al.
    Am J Psychiatry. 2019;176:574-575.
    PubMed     Text format    


  23. CAO H, Cannon TD
    Cerebellar Dysfunction and Schizophrenia: From "Cognitive Dysmetria" to a Potential Therapeutic Target.
    Am J Psychiatry. 2019;176:498-500.
    PubMed     Text format    


  24. BULLMORE E
    Cortical Thickness and Connectivity in Schizophrenia.
    Am J Psychiatry. 2019;176:505-506.
    PubMed     Text format    


  25. LAWN RB, Sallis HM, Taylor AE, Wootton RE, et al
    Comment on the Relationship Between Common Variant Schizophrenia Liability and Number of Offspring in the UK Biobank.
    Am J Psychiatry. 2019;176:573-574.
    PubMed     Text format    


  26. SMUCNY J, Lesh TA, Carter CS
    Baseline Frontoparietal Task-Related BOLD Activity as a Predictor of Improvement in Clinical Symptoms at 1-Year Follow-Up in Recent-Onset Psychosis.
    Am J Psychiatry. 2019 Jul 1:appiajp201918101126.
    PubMed     Text format     Abstract available


  27. ZANELLI J, Mollon J, Sandin S, Morgan C, et al
    Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode.
    Am J Psychiatry. 2019 Jul 1:appiajp201918091088.
    PubMed     Text format     Abstract available


  28. HAWCO C, Buchanan RW, Calarco N, Mulsant BH, et al
    Separable and Replicable Neural Strategies During Social Brain Function in People With and Without Severe Mental Illness.
    Am J Psychiatry. 2019;176:521-530.
    PubMed     Text format     Abstract available


    June 2019
  29. TANG Y, Pasternak O, Kubicki M, Rathi Y, et al
    Altered Cellular White Matter But Not Extracellular Free Water on Diffusion MRI in Individuals at Clinical High Risk for Psychosis.
    Am J Psychiatry. 2019 Jun 24:appiajp201918091044.
    PubMed     Text format     Abstract available


  30. LIZANO P, Lutz O, Ling G, Lee AM, et al
    Association of Choroid Plexus Enlargement With Cognitive, Inflammatory, and Structural Phenotypes Across the Psychosis Spectrum.
    Am J Psychiatry. 2019 Jun 5:appiajp201918070825.
    PubMed     Text format     Abstract available


  31. WANNAN CMJ, Cropley VL, Chakravarty MM, Bousman C, et al
    Evidence for Network-Based Cortical Thickness Reductions in Schizophrenia.
    Am J Psychiatry. 2019 Jun 5:appiajp201918040380.
    PubMed     Text format     Abstract available


  32. MULLINS N, Bigdeli TB, Borglum AD, Coleman JRI, et al
    GWAS of Suicide Attempt in Psychiatric Disorders and Association With Major Depression Polygenic Risk Scores.
    Am J Psychiatry. 2019 Jun 5:appiajp201918080957.
    PubMed     Text format     Abstract available


  33. PARDINAS AF, Nalmpanti M, Pocklington AJ, Legge SE, et al
    Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism.
    Am J Psychiatry. 2019;176:477-486.
    PubMed     Text format     Abstract available


    May 2019
  34. NUCIFORA LG, MacDonald ML, Lee BJ, Peters ME, et al
    Increased Protein Insolubility in Brains From a Subset of Patients With Schizophrenia.
    Am J Psychiatry. 2019 May 6:appiajp201918070864.
    PubMed     Text format     Abstract available


  35. KENDLER KS, Ohlsson H, Sundquist J, Sundquist K, et al
    Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample.
    Am J Psychiatry. 2019 May 6:appiajp201918101217.
    PubMed     Text format     Abstract available


    April 2019
  36. BUCHANAN A, Sint K, Swanson J, Rosenheck R, et al
    Correlates of Future Violence in People Being Treated for Schizophrenia.
    Am J Psychiatry. 2019 Apr 24:appiajp201918080909.
    PubMed     Text format     Abstract available


  37. VINOGRADOV S
    Has the Time Come for Cognitive Remediation in Schizophrenia...Again?
    Am J Psychiatry. 2019;176:262-264.
    PubMed     Text format    


    March 2019
  38. BEST MW, Milanovic M, Iftene F, Bowie CR, et al
    A Randomized Controlled Trial of Executive Functioning Training Compared With Perceptual Training for Schizophrenia Spectrum Disorders: Effects on Neurophysiology, Neurocognition, and Functioning.
    Am J Psychiatry. 2019 Mar 8:appiajp201818070849.
    PubMed     Text format     Abstract available


  39. MARTIN WF, Correll CU, Weiden PJ, Jiang Y, et al
    Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Am J Psychiatry. 2019 Mar 8:appiajp201818030280.
    PubMed     Text format     Abstract available


    February 2019
  40. SANCHEZ-ROIGE S, Palmer AA, Fontanillas P, Elson SL, et al
    Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts.
    Am J Psychiatry. 2019;176:107-118.
    PubMed     Text format     Abstract available


    January 2019
  41. BRADY RO JR, Gonsalvez I, Lee I, Ongur D, et al
    Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia.
    Am J Psychiatry. 2019 Jan 30:appiajp201818040429.
    PubMed     Text format     Abstract available


  42. JALBRZIKOWSKI M, Murty VP, Tervo-Clemmens B, Foran W, et al
    Age-Associated Deviations of Amygdala Functional Connectivity in Youths With Psychosis Spectrum Disorders: Relevance to Psychotic Symptoms.
    Am J Psychiatry. 2019 Jan 18:appiajp201818040443.
    PubMed     Text format     Abstract available


  43. ESCOTT-PRICE V, Pardinas AF, Santiago E, Walters J, et al
    The Relationship Between Common Variant Schizophrenia Liability and Number of Offspring in the UK Biobank.
    Am J Psychiatry. 2019 Jan 4:appiajp201818020140.
    PubMed     Text format     Abstract available


  44. WEINBERGER DR
    Polygenic Risk Scores in Clinical Schizophrenia Research.
    Am J Psychiatry. 2019;176:3-4.
    PubMed     Text format    


  45. WEINBERGER DR
    Thinking About Schizophrenia in an Era of Genomic Medicine.
    Am J Psychiatry. 2019;176:12-20.
    PubMed     Text format     Abstract available


    December 2018
  46. GHOSH A, Noble D
    The Influence of Unmeasured Confounding Effects in a Study of Antipsychotic Discontinuation in First-Episode Schizophrenia.
    Am J Psychiatry. 2018;175:1266-1267.
    PubMed     Text format    


    November 2018
  47. RIGLIN L, Hammerton G, Heron J, Collishaw S, et al
    Developmental Contributions of Schizophrenia Risk Alleles and Childhood Peer Victimization to Early-Onset Mental Health Trajectories.
    Am J Psychiatry. 2018 Nov 29:appiajp201818010075.
    PubMed     Text format     Abstract available


  48. BERGEN SE, Ploner A, Howrigan D, O'Donovan MC, et al
    Joint Contributions of Rare Copy Number Variants and Common SNPs to Risk for Schizophrenia.
    Am J Psychiatry. 2018 Nov 5:appiajp201817040467.
    PubMed     Text format     Abstract available


  49. ZHANG JP, Robinson D, Yu J, Gallego J, et al
    Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis.
    Am J Psychiatry. 2018 Nov 5:appiajp201817121363.
    PubMed     Text format     Abstract available


    October 2018
  50. MARTINEZ A, Gaspar PA, Hillyard SA, Andersen SK, et al
    Impaired Motion Processing in Schizophrenia and the Attenuated Psychosis Syndrome: Etiological and Clinical Implications.
    Am J Psychiatry. 2018 Oct 3:appiajp201818010072.
    PubMed     Text format     Abstract available


  51. DI PRINZIO P, Morgan VA, Bjork J, Croft M, et al
    Intellectual Disability and Psychotic Disorders in Children: Association With Maternal Severe Mental Illness and Exposure to Obstetric Complications in a Whole-Population Cohort.
    Am J Psychiatry. 2018 Oct 3:appiajp201817101153.
    PubMed     Text format     Abstract available


    September 2018
  52. ZHANG T, Li H, Tang Y, Niznikiewicz MA, et al
    Validating the Predictive Accuracy of the NAPLS-2 Psychosis Risk Calculator in a Clinical High-Risk Sample From the SHARP (Shanghai At Risk for Psychosis) Program.
    Am J Psychiatry. 2018;175:906-908.
    PubMed     Text format    


    August 2018
  53. XIAO Y, Sun H, Shi S, Jiang D, et al
    White Matter Abnormalities in Never-Treated Patients With Long-Term Schizophrenia.
    Am J Psychiatry. 2018 Aug 2:appiajp201817121402.
    PubMed     Text format     Abstract available


  54. VERMEULEN JM, Schirmbeck F, Blankers M, van Tricht M, et al
    Association Between Smoking Behavior and Cognitive Functioning in Patients With Psychosis, Siblings, and Healthy Control Subjects: Results From a Prospective 6-Year Follow-Up Study.
    Am J Psychiatry. 2018 Aug 2:appiajp201818010069.
    PubMed     Text format     Abstract available


  55. KAHN RS
    On the Continued Benefit of Antipsychotics After the First Episode of Schizophrenia.
    Am J Psychiatry. 2018;175:712-713.
    PubMed     Text format    


    July 2018
  56. KRIVINKO JM, Erickson SL, Ding Y, Sun Z, et al
    Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease.
    Am J Psychiatry. 2018 Jul 19:appiajp201817080858.
    PubMed     Text format     Abstract available


  57. ROBERTSON AG, Easter MM, Lin H, Frisman LK, et al
    Medication-Assisted Treatment for Alcohol-Dependent Adults With Serious Mental Illness and Criminal Justice Involvement: Effects on Treatment Utilization and Outcomes.
    Am J Psychiatry. 2018;175:665-673.
    PubMed     Text format     Abstract available


    June 2018
  58. EL-MALLAKH RS, Furdek C
    Cycloid Psychosis.
    Am J Psychiatry. 2018;175:502-505.
    PubMed     Text format    


    May 2018
  59. NELSON JC, Bickford D, Delucchi K, Fiedorowicz JG, et al
    Risk of Psychosis in Recurrent Episodes of Psychotic and Nonpsychotic Major Depressive Disorder: A Systematic Review and Meta-Analysis.
    Am J Psychiatry. 2018 May 24:appiajp201817101138.
    PubMed     Text format     Abstract available


  60. FARRELL M, Lichtenstein M, Crowley JJ, Filmyer DM, et al
    Developmental Delay, Treatment-Resistant Psychosis, and Early-Onset Dementia in a Man With 22q11 Deletion Syndrome and Huntington's Disease.
    Am J Psychiatry. 2018;175:400-407.
    PubMed     Text format    


  61. ROSENHECK R
    Toward Dissemination of Secondary Prevention for Psychosis.
    Am J Psychiatry. 2018;175:393-394.
    PubMed     Text format    


    April 2018
  62. TIIHONEN J, Tanskanen A, Taipale H
    20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
    Am J Psychiatry. 2018 Apr 6:appiajp201817091001.
    PubMed     Text format     Abstract available


  63. JEZEQUEL J, Lepleux M, Kahn RS, Honnorat J, et al
    Molecular Pathogenicity of Anti-NMDA Receptor Autoantibody From Patients With First-Episode Psychosis.
    Am J Psychiatry. 2018;175:382-383.
    PubMed     Text format    


  64. GHOSE S
    Substance-Induced Psychosis: An Indicator of Development of Primary Psychosis?
    Am J Psychiatry. 2018;175:303-304.
    PubMed     Text format    


  65. DAMIANI S, Fusar-Poli L
    The Cats of Louis Wain: A Thousand Ways to Draw One's Mind.
    Am J Psychiatry. 2018;175:315.
    PubMed     Text format    


    March 2018
  66. ANDERSON KK, Norman R, MacDougall A, Edwards J, et al
    Effectiveness of Early Psychosis Intervention: Comparison of Service Users and Nonusers in Population-Based Health Administrative Data.
    Am J Psychiatry. 2018 Mar 2:appiajp201717050480.
    PubMed     Text format     Abstract available


  67. KAUPPI K, Rosenthal SB, Lo MT, Sanyal N, et al
    Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia.
    Am J Psychiatry. 2018 Mar 2:appiajp201717040410.
    PubMed     Text format     Abstract available


  68. NOORDSY DL, Burgess JD, Hardy KV, Yudofsky LM, et al
    Therapeutic Potential of Physical Exercise in Early Psychosis.
    Am J Psychiatry. 2018;175:209-214.
    PubMed     Text format    


    February 2018
  69. PAYNE JL
    The Psychoses of Menstruation and Childbearingby Ian Brockington, M.D., F.R.C.P. Cambridge, England, Cambridge University Press, 2017, 391 pp., $140.00 (hardcover).
    Am J Psychiatry. 2018;175:190-191.
    PubMed     Text format    


  70. GOFF DC
    Optimizing the Pharmacologic Treatment of Individuals With First-Episode Psychosis.
    Am J Psychiatry. 2018;175:101-102.
    PubMed     Text format    


  71. ROBINSON DG, Schooler NR, Correll CU, John M, et al
    Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention.
    Am J Psychiatry. 2018;175:169-179.
    PubMed     Text format     Abstract available


    December 2017
  72. MCGUIRE P, Robson P, Cubala WJ, Vasile D, et al
    Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
    Am J Psychiatry. 2017 Dec 15:appiajp201717030325.
    PubMed     Text format     Abstract available


  73. HAMILTON HK, Williams TJ, Ventura J, Jasperse LJ, et al
    Clinical and Cognitive Significance of Auditory Sensory Processing Deficits in Schizophrenia.
    Am J Psychiatry. 2017 Dec 5:appiajp201716111203.
    PubMed     Text format     Abstract available


    November 2017
  74. LIVNY A, Reichenberg A, Fruchter E, Yoffe R, et al
    A Population-Based Longitudinal Study of Symptoms and Signs Before the Onset of Psychosis.
    Am J Psychiatry. 2017 Nov 28:appiajp201716121384.
    PubMed     Text format     Abstract available


  75. STARZER MSK, Nordentoft M, Hjorthoj C
    Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis.
    Am J Psychiatry. 2017 Nov 28:appiajp201717020223.
    PubMed     Text format     Abstract available


  76. GOES FS, Sawa A
    Psychosis Beyond the 22q11.2 Deletion: Do Additional Genetic Factors Play a Role?
    Am J Psychiatry. 2017;174:1027-1029.
    PubMed     Text format    


  77. SCHOOLER NR
    Long-Term Outcomes of Psychosis: Naturalistic Follow-Up After Initial Hospitalization.
    Am J Psychiatry. 2017;174:1030-1031.
    PubMed     Text format    


  78. KOTOV R, Fochtmann L, Li K, Tanenberg-Karant M, et al
    Declining Clinical Course of Psychotic Disorders Over the Two Decades Following First Hospitalization: Evidence From the Suffolk County Mental Health Project.
    Am J Psychiatry. 2017;174:1064-1074.
    PubMed     Text format     Abstract available


  79. VELTHORST E, Fett AJ, Reichenberg A, Perlman G, et al
    The 20-Year Longitudinal Trajectories of Social Functioning in Individuals With Psychotic Disorders.
    Am J Psychiatry. 2017;174:1075-1085.
    PubMed     Text format     Abstract available


    October 2017
  80. KANE JM
    Clozapine Reduces All-Cause Mortality.
    Am J Psychiatry. 2017;174:920-921.
    PubMed     Text format    


  81. RAHMAN T, Ash DM, Lauriello J, Rawlani R, et al
    Misleading Guidance From Pharmacogenomic Testing.
    Am J Psychiatry. 2017;174:922-924.
    PubMed     Text format    


    September 2017
  82. LEVITT JJ, Nestor PG, Levin L, Pelavin P, et al
    Reduced Structural Connectivity in Frontostriatal White Matter Tracts in the Associative Loop in Schizophrenia.
    Am J Psychiatry. 2017 Sep 15:appiajp201716091046.
    PubMed     Text format     Abstract available


    August 2017
  83. SANDOVAL LR, Torous J, Keshavan MS
    Smartphones for Smarter Care? Self-Management in Schizophrenia.
    Am J Psychiatry. 2017;174:725-728.
    PubMed     Text format    


    July 2017
  84. DAVIDSON M, Saoud J, Staner C, Noel N, et al
    Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Am J Psychiatry. 2017 Jul 28:appiajp201717010122.
    PubMed     Text format     Abstract available


  85. BASSETT AS, Lowther C, Merico D, Costain G, et al
    Rare Genome-Wide Copy Number Variation and Expression of Schizophrenia in 22q11.2 Deletion Syndrome.
    Am J Psychiatry. 2017 Jul 28:appiajp201716121417.
    PubMed     Text format     Abstract available


  86. WIMBERLEY T, MacCabe JH, Laursen TM, Sorensen HJ, et al
    Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia.
    Am J Psychiatry. 2017 Jul 28:appiajp201716091097.
    PubMed     Text format     Abstract available


  87. ANDREASSEN OA
    Diabetes and Schizophrenia-New Findings for an Old Puzzle.
    Am J Psychiatry. 2017;174:616-617.
    PubMed     Text format    


  88. PHILIP NS, Nelson BG, Frohlich F, Lim KO, et al
    Low-Intensity Transcranial Current Stimulation in Psychiatry.
    Am J Psychiatry. 2017;174:628-639.
    PubMed     Text format     Abstract available


  89. SHARMA A, Wolf DH, Ciric R, Kable JW, et al
    Common Dimensional Reward Deficits Across Mood and Psychotic Disorders: A Connectome-Wide Association Study.
    Am J Psychiatry. 2017;174:657-666.
    PubMed     Text format     Abstract available


    June 2017
  90. COYLE JT
    Cortical Pyramidal Neurons Show a Selective Loss of New Synapses in Chronic Schizophrenia.
    Am J Psychiatry. 2017;174:510-511.
    PubMed     Text format    


    May 2017
  91. LEUCHT S, Leucht C, Huhn M, Chaimani A, et al
    Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
    Am J Psychiatry. 2017 May 25:appiajp201716121358.
    PubMed     Text format     Abstract available


  92. GOFF DC, Falkai P, Fleischhacker WW, Girgis RR, et al
    The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia.
    Am J Psychiatry. 2017 May 5:appiajp201716091016.
    PubMed     Text format     Abstract available


  93. HORVITZ-LENNON M, Mattke S, Predmore Z, Howes OD, et al
    The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia.
    Am J Psychiatry. 2017;174:421-426.
    PubMed     Text format    


  94. NAKIMULI-MPUNGU E
    Our Most Troubling Madness: Case Studies in Schizophrenia Across Culturesedited by T.M. Luhrmann and Jocelyn Marrow. Oakland, University of California Press, 2016, 304 pp., $29.95 (paperback).
    Am J Psychiatry. 2017;174:490.
    PubMed     Text format    


  95. HAUSER RA, Factor SA, Marder SR, Knesevich MA, et al
    KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Am J Psychiatry. 2017;174:476-484.
    PubMed     Text format     Abstract available


  96. BOU KHALIL R
    On the Magical Thinking Related to Mental Health in Chad.
    Am J Psychiatry. 2017;174:427-428.
    PubMed     Text format    


    April 2017
  97. ROSENHECK RA, Estroff SE, Sint K, Lin H, et al
    Incomes and Outcomes: Social Security Disability Benefits in First-Episode Psychosis.
    Am J Psychiatry. 2017 Apr 21:appiajp201716111273.
    PubMed     Text format     Abstract available


  98. LAVRETSKY H
    Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation.
    Am J Psychiatry. 2017;174:307-308.
    PubMed     Text format    


    March 2017
  99. MACDONALD ML, Alhassan J, Newman JT, Richard M, et al
    Selective Loss of Smaller Spines in Schizophrenia.
    Am J Psychiatry. 2017 Mar 31:appiajp201716070814.
    PubMed     Text format     Abstract available


  100. PATERSON C, Wang Y, Hyde TM, Weinberger DR, et al
    Temporal, Diagnostic, and Tissue-Specific Regulation of NRG3 Isoform Expression in Human Brain Development and Affective Disorders.
    Am J Psychiatry. 2017;174:256-265.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: